Helicobacter pylori and peptic ulcer disease

M. Feldman, W. L. Peterson

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Medical therapy for duodenal or gastric ulcer disease has traditionally involved gastric acid anti-secretory therapy for 4 to 8 weeks to promote initial healing and indefinitely to prevent recurrences of ulcer. The discovery of Helicobacter pylori in most patients with peptic ulcer disease has led to a change in this approach. Therapy designed to eradicate H pylori may facilitate ulcer healing with acid antisecretory agents and, more important, may greatly reduce the incidence of ulcer recurrence, obviating the need for maintenance antisecretory therapy. Regimens designed to eradicate H pylori are difficult to comply with, however, and are associated with adverse effects in some patients. In this article we review the diagnosis and treatment of H pylori infection in patients with peptic ulcer disease and make recommendations regarding the use of conventional ulcer therapies and therapies designed to eradicate H pylori.

Original languageEnglish (US)
Pages (from-to)555-559
Number of pages5
JournalWestern Journal of Medicine
Issue number5
StatePublished - Jan 1 1993

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Helicobacter pylori and peptic ulcer disease'. Together they form a unique fingerprint.

Cite this